Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis by Bonga KN, et al (Obstet Gynecol. 2024 Mar 1;143(3):393-402.)

Serge Rozenberg

Bonga KN, et al (Obstet Gynecol. 2024 Mar 1;143(3):393-402. doi: 10.1097/AOG.0000000000005508. Epub 2024 Jan 16. PMID: 38227939.) evaluated the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause. They identified 330 articles, of which five studies with six reports were included in a meta-analysis.

A total of 2,168 participants from five randomized clinical trials (six reports) were included. Fezolinetant significantly lowered VMS frequency, with pooled mean difference of 2.62 (95% CI, 1.84-3.41). The pooled mean difference for fezolinetant compared with placebo for the MENQOL (Menopause-Specific Quality of Life) measure was -0.60 (95% CI, -0.92 to -0.28), and the mean percentage improvement in VMS frequency was 22.51% (95% CI, 15.35-29.67). Fezolinetant was associated with improvement in sleep quality when compared with placebo.

No data was found

Latest news

RIZIV-INAMI Consensus conference on menopause 30.5.24